Gene Expression Analysis Reveals a Subset of TP53mutant-like AML with Wild Type TP53 and Poor Prognosis

被引：0
|
作者：
Lee, Yoonkyu [1 ,2 ,3 ]
Myers, Chad [2 ,4 ,5 ]
Sachs, Zohar [1 ,2 ,5 ]
机构：
[1] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN USA
[2] Univ Minnesota, Bioinformat & Computat Biol Program, Rochester, MN USA
[3] Univ Minnesota, Minneapolis, MN USA
[4] Univ Minnesota, Dept Comp Sci & Engn, Minneapolis, MN USA
[5] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-167021
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9108 / 9109
页数：2
相关论文
共 50 条
  • [31] AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy
    Yan, Bowen
    Claxton, David
    Huang, Suming
    Qiu, Yi
    EXPERIMENTAL HEMATOLOGY, 2020, 87 : 13 - 19
  • [32] CMML PATIENTS WITH LOW EXPRESSION OF TP53 POINT TO AML TRANSFORMATION
    Imanci, A.
    Laplane, L.
    Selimoglu-Buet, D.
    Morabito, M.
    Francillette, M.
    Bouchra, B.
    Wagner-Ballon, O.
    Thepot, S.
    Porteu, F.
    Fenaux, P.
    Figueroa, M.
    Itzykson, R.
    Solary, E.
    Droin, N.
    LEUKEMIA RESEARCH, 2023, 128
  • [33] TP53 Mutations are Present in Targeted NGS Profiles from EGFR Wild type, NSCLC Patients with Poor Prognosis
    Mellet, H.
    Jackson, L.
    Hahn, W.
    Dupuis, N.
    Weaver, A.
    Greer, J.
    Pestano, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 1012 - 1012
  • [34] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    A Stengel
    W Kern
    T Haferlach
    M Meggendorfer
    A Fasan
    C Haferlach
    Leukemia, 2017, 31 : 705 - 711
  • [35] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    Stengel, A.
    Kern, W.
    Haferlach, T.
    Meggendorfer, M.
    Fasan, A.
    Haferlach, C.
    LEUKEMIA, 2017, 31 (03) : 705 - 711
  • [36] Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
    Ignacio, Rosa Mistica C.
    Lee, Eun-Sook
    Wilson, Andrew J.
    Beeghly-Fadiel, Alicia
    Whalen, Margaret M.
    Son, Deok-Soo
    IMMUNE NETWORK, 2018, 18 (04)
  • [37] KEVETRIN TARGETS TP53 WILD-TYPE AND MUTANT ACUTE MYELOID LEUKEMIA CELLS
    Napolitano, R.
    De Matteis, S.
    Carloni, S.
    Ghetti, M.
    Liverani, C.
    Bochicchio, M. T.
    di Rora, A. Ghelli Luserna
    Fontana, M. C.
    Padella, A.
    Mercatali, L.
    Menon, K.
    Musuraca, G.
    Martinelli, G.
    Simonetti, G.
    HAEMATOLOGICA, 2020, 105 : S88 - S89
  • [38] Immunoprofile of tumour cells, in wild-type- versus mutant TP53 gastric carcinomas
    Gurzu, S.
    Sugimura, H.
    Van Staden, R. I.
    Jung, I.
    VIRCHOWS ARCHIV, 2020, 477 : S185 - S185
  • [39] NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells
    Zhang, Yu
    Yu, Hao
    He, Mengyao
    Liu, Wenchao
    Xiao, Shengyou
    Wang, Xiangting
    Huang, Ping
    Huang, Qiang
    NEOPLASMA, 2024, 71 (03) : 255 - 265
  • [40] TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients
    Berns, EMJJ
    Klijn, JGM
    Smid, M
    vanStaveren, IL
    Look, MP
    vanPutten, WLJ
    Foekens, JA
    GENES CHROMOSOMES & CANCER, 1996, 16 (03): : 170 - 179
12345